

Cohort – Maintaining function and well-being in later life

<https://neurodegenerationresearch.eu/survey/cohort-maintaining-function-and-well-being-in-later-life/>

Title of the cohort

Cohort – Maintaining function and well-being in later life

Acronym for cohort

CFAS Wales

Name of Principal Investigator

Title Professor

First name Bob

Last name Woods

Address of institution where award is held

Institution Bangor University

Street Address 45, College Road

City Bangor

Postcode LL57 2DG

Country

United Kingdom

Website

<http://cfaswales.bangor.ac.uk/>

Contact email

g.windle@bangor.ac.uk

Funding source

ESRC

HEFCW

1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias

When studies on the above condition(s) are expected to become possible

2016 – 2025

2a. Stated aim of the cohort

To identify biopsychosocial influences on the development of cognitive impairment and the maintenance of well-being in later life.

2b. Features distinguishing this cohort from other population cohorts

This cohort links in with the CFAS-II study, but includes additional measures relating to social support, bilingualism and resilience.

3a. i) Number of publications that involve use of cohort to date

0

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

Will augment the CFAS-II study, in comparing prevalence and incidence of cognitive impairment with the CFAS-I cohort fifteen years previously. Will examine influence of cognitive reserve on development of cognitive impairment.

4a. Study criteria: age range of participants at recruitment

Age in years from: 65

To ('until death' if applicable): until death

4b. Study criteria: inclusion criteria

All people in defined geographical areas aged over 65, registered with a general practitioner, including those in institutions.

4c. Study criteria: exclusion criteria

Terminal illness. Inability to speak English or Welsh.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

AGECAT

CamCog

6b. Additional measures for participants with a clinical disorder

No

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

No

7. Study design

- Prospective cohort

- Longitudinal

8. Cases matched by

- Age
- Sex

9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date

01-08-2011

10a. ii) Data collection end date

31-03-2015

10a iii) Data collection for this study is

- At the planning stage

10b. Plans to continue the cohort study beyond the current projected end date

11. Data collected

Only through the study

12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available

Data summarised in database No

Database is web-based No

Database on spreadsheet No

Database is on paper No

Other (specify) No

Language used:

13b. Format and availability of data held as individual records

Yes/No % available

Data held as individual records No

Data is web-based No

Data held on computer based records No

Data held on cards No

Other (specify)

Language used:

14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups

- Access Committee mechanism

15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

No

16b. i) Description of available tissues/samples/DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

17. Is information on biological characteristics available to other groups

- No